Maravai LifeSciences (MRVI) Stock: Growth Catalysts Remain
seekingalpha.com
news
2022-10-22 09:36:54

skynesher/E+ via Getty Images In November 2020 I concluded that Maravai LifeSciences (NASDAQ:MRVI) was a real Covid-19 beneficiary, as the market gave the company a welcome debut when it went public. The company plays a crucial role in drug development and even played a role in the Pfizer (PFE)/BioNTech (BNTX) vaccine, the talk of the day of course. With the growth prospects looking sound with or without a pandemic, I believed that the outlook for the business was sound, yet it simply felt as if valuations were pushed up a bit too much at the time.
